Mark W. Jackwood, Samuel Bogoch, Elenore S. Bogoch, Deborah Hilt, Susan M. Williams, “Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus,” Avian Diseases 53(4), 613-617, (1 December 2009):
The company’s ReplivaxTM platform produces sub-unit purely synthetic DNA/RNA peptide vaccines which are built on the company’s discovery of sequences in the genome related to rapid replication. Theses sequences increase in concentration in the genome prior to outbreaks and have proved to be immogenic. [LINK]. The vaccines, are designed within a week and can be produced within two weeks by sold phase synthesis. The vaccines contain no biologics therefore are less likely to cause side effects.
Surveillance of the genome with the company’s BIORADAR genomic surveillance software tracks changes in the genome of the virus. The Replivax technology allows for a new vaccine formulation to be produced in less than two weeks to combat mutation in the virus.
No other vaccine in the world can be produced with the same speed and economy as the Replikins vaccines. Existing solid phase synthesis factories around the world can produce enough vaccine in weeks to meet global pandemic needs. The cost of producing the vaccine is pennies per dose. Replikins has completed successful animal trials with its H5N1 Replikins vaccine in chickens.
“…these data indicate that a replikin peptide vaccine specifically made against the H5N1 Black Duck/NC/674-964/06 and administered 3 times to the upper –respiratory tract, was capable of protecting chickens from infection and shedding of the homologous virus, which is extremely important because reduced virus shedding and transmission decreases the potential for H5-LPAI viruses to become HPAI viruses. The study is also important because it shows that the vaccine can be effectively mass delivered to the upper respiratory tract.” https://doi.org/10.1637/8892-042509-ResNote.1.